Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Acquisitions & Divestments: 2012-2024

Historic Change in Acquisitions & Divestments for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to $139.8 million.

  • Theravance Biopharma's Change in Acquisitions & Divestments fell 10.90% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.5 million, marking a year-over-year increase of 8.37%. This contributed to the annual value of $139.8 million for FY2024, which is 95.88% up from last year.
  • Per Theravance Biopharma's latest filing, its Change in Acquisitions & Divestments stood at $139.8 million for FY2024, which was up 95.88% from $71.4 million recorded in FY2023.
  • In the past 5 years, Theravance Biopharma's Change in Acquisitions & Divestments registered a high of $399.3 million during FY2020, and its lowest value of $71.4 million during FY2023.
  • In the last 3 years, Theravance Biopharma's Change in Acquisitions & Divestments had a median value of $139.8 million in 2024 and averaged $123.1 million.
  • As far as peak fluctuations go, Theravance Biopharma's Change in Acquisitions & Divestments slumped by 54.82% in 2023, and later soared by 95.88% in 2024.
  • Over the past 5 years, Theravance Biopharma's Change in Acquisitions & Divestments (Yearly) stood at $399.3 million in 2020, then dropped by 28.33% to $286.2 million in 2021, then slumped by 44.79% to $158.0 million in 2022, then slumped by 54.82% to $71.4 million in 2023, then spiked by 95.88% to $139.8 million in 2024.